[
  {
    "ts": "2026-02-28T01:14:59+00:00",
    "headline": "Is It Too Late To Consider Johnson & Johnson (JNJ) After Its Strong 1 Year Rally?",
    "summary": "If you are wondering whether Johnson & Johnson is still fairly priced after its recent run, this article will help you weigh what you are paying against what you are getting. The stock last closed at US$248.43, with reported returns of 2.4% over 7 days, 9.1% over 30 days, 19.8% year to date, 54.7% over 1 year and 83.3% over 5 years. These figures may have some investors reassessing both upside potential and risk. Recent headlines around Johnson & Johnson have continued to focus on its...",
    "url": "https://finance.yahoo.com/news/too-consider-johnson-johnson-jnj-011459833.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "062b250b-5711-3cee-a997-e3040dc8aefc",
      "content": {
        "id": "062b250b-5711-3cee-a997-e3040dc8aefc",
        "contentType": "STORY",
        "title": "Is It Too Late To Consider Johnson & Johnson (JNJ) After Its Strong 1 Year Rally?",
        "description": "",
        "summary": "If you are wondering whether Johnson & Johnson is still fairly priced after its recent run, this article will help you weigh what you are paying against what you are getting. The stock last closed at US$248.43, with reported returns of 2.4% over 7 days, 9.1% over 30 days, 19.8% year to date, 54.7% over 1 year and 83.3% over 5 years. These figures may have some investors reassessing both upside potential and risk. Recent headlines around Johnson & Johnson have continued to focus on its...",
        "pubDate": "2026-02-28T01:14:59Z",
        "displayTime": "2026-02-28T01:14:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/too-consider-johnson-johnson-jnj-011459833.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/too-consider-johnson-johnson-jnj-011459833.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-28T07:18:19+00:00",
    "headline": "Is Blackstone Inc. (BX) One of the Best Cheap Blue Chip Stocks to Buy According to Analysts?",
    "summary": "Blackstone Inc. (NYSE:BX) is one of the best cheap blue chip stocks to buy according to analysts. Blackstone Inc. (NYSE:BX) reported on February 23 that Blackstone Life Sciences (BXLS) announced a research and development funding agreement to advance the clinical development of bleximenib, which is an investigational oral menin inhibitor, for acute myeloid leukemia (AML). […]",
    "url": "https://finance.yahoo.com/news/blackstone-inc-bx-one-best-071819270.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "06de09ba-6a5e-368b-b02e-7707eb3f1427",
      "content": {
        "id": "06de09ba-6a5e-368b-b02e-7707eb3f1427",
        "contentType": "STORY",
        "title": "Is Blackstone Inc. (BX) One of the Best Cheap Blue Chip Stocks to Buy According to Analysts?",
        "description": "",
        "summary": "Blackstone Inc. (NYSE:BX) is one of the best cheap blue chip stocks to buy according to analysts. Blackstone Inc. (NYSE:BX) reported on February 23 that Blackstone Life Sciences (BXLS) announced a research and development funding agreement to advance the clinical development of bleximenib, which is an investigational oral menin inhibitor, for acute myeloid leukemia (AML). […]",
        "pubDate": "2026-02-28T07:18:19Z",
        "displayTime": "2026-02-28T07:18:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/61bbb14c4ddd66e5b63cb700571aa36f",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fKJKqtgdrhNov47FXvVBiQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/61bbb14c4ddd66e5b63cb700571aa36f.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qEAccTPBiHXt1yByaNidKA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/61bbb14c4ddd66e5b63cb700571aa36f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/blackstone-inc-bx-one-best-071819270.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/blackstone-inc-bx-one-best-071819270.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BX"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-28T15:55:02+00:00",
    "headline": "Kenvue Inc. (KVUE): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Kenvue Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on KVUE. Kenvue Inc.’s share was trading at $18.66 as of February 19th. KVUE’s trailing and forward P/E were 24.93 and 17.01, respectively according to Yahoo Finance. Kenvue, the newly independent consumer health company spun […]",
    "url": "https://finance.yahoo.com/news/kenvue-inc-kvue-bull-case-155502646.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "4f469799-770c-35f0-9a61-b35fc91f9862",
      "content": {
        "id": "4f469799-770c-35f0-9a61-b35fc91f9862",
        "contentType": "STORY",
        "title": "Kenvue Inc. (KVUE): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Kenvue Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on KVUE. Kenvue Inc.’s share was trading at $18.66 as of February 19th. KVUE’s trailing and forward P/E were 24.93 and 17.01, respectively according to Yahoo Finance. Kenvue, the newly independent consumer health company spun […]",
        "pubDate": "2026-02-28T15:55:02Z",
        "displayTime": "2026-02-28T15:55:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/5f621a33d1222663fde60a4644b4a405",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Johnson & Johnson JNJ headache tylenol pain acetaminophen pill relief display health",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wQZyY2sDtP7_jzDf__WfDQ--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/5f621a33d1222663fde60a4644b4a405.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lIPfAsGccG_VdXaqy_efyw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5f621a33d1222663fde60a4644b4a405.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kenvue-inc-kvue-bull-case-155502646.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kenvue-inc-kvue-bull-case-155502646.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-28T15:25:00+00:00",
    "headline": "Middleby Is Spinning Off Its Food Processing Segment After a $540 Million Asset Sale. Can the Breakup Close Its Valuation Gap?",
    "summary": "Middleby is splitting up, and the sum-of-the-parts math looks promising if margins cooperate.",
    "url": "https://www.fool.com/investing/2026/02/28/middleby-is-spinning-off-its-food-processing-segme/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "ae3c5f92-223d-31d6-97be-60a85d57e0da",
      "content": {
        "id": "ae3c5f92-223d-31d6-97be-60a85d57e0da",
        "contentType": "STORY",
        "title": "Middleby Is Spinning Off Its Food Processing Segment After a $540 Million Asset Sale. Can the Breakup Close Its Valuation Gap?",
        "description": "",
        "summary": "Middleby is splitting up, and the sum-of-the-parts math looks promising if margins cooperate.",
        "pubDate": "2026-02-28T15:25:00Z",
        "displayTime": "2026-02-28T15:25:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/d42e10f70d3a08c4c821b18dcf9115ee",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Person looking at a tablet in a food processing plant.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HIEOx046WbRQsKYVXKF4mQ--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/d42e10f70d3a08c4c821b18dcf9115ee.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XA1rTXKcxqqouacxVzfcog--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/d42e10f70d3a08c4c821b18dcf9115ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/28/middleby-is-spinning-off-its-food-processing-segme/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/middleby-spinning-off-food-processing-152500072.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            },
            {
              "symbol": "HON"
            },
            {
              "symbol": "DD"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MIDD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]